AC Immune poleaxed on Alzheimer’s study failShares in AC Immune have collapsed after partner Genentech revealed its tau-targeting Alzheimer’s drug semorinemab had flunked a Share XAC Immune poleaxed on Alzheimer’s study failhttps://pharmaphorum.com/news/ac-immune-poleaxed-on-alzheimers-study-fail/
Roche doubles down on tau for Alzheimer’s, licensing UCB drug for $120mRoche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a Share XRoche doubles down on tau for Alzheimer’s, licensing UCB drug for $120mhttps://pharmaphorum.com/news/roche-doubles-down-on-tau-for-alzheimers-licensing-ucb-drug-for-120m/
A bright future for CNS and Alzheimer’s?Swiss biotech Asceneuron is developing what could be the first treatment for progressive supranuclear palsy (PSP), a rare Share XA bright future for CNS and Alzheimer’s?https://pharmaphorum.com/r-d/views-analysis-r-d/a-bright-future-for-cns-and-alzheimers/
